Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > March 2014 - Volume 30 - Issue 3 > Adverse Events Attributable to Nocebo in Randomized Controll...
Text sizing:
A
A
A
Clinical Journal of Pain:
doi: 10.1097/AJP.0000000000000073
Erratum

Adverse Events Attributable to Nocebo in Randomized Controlled Drug Trials in Fibromyalgia Syndrome and Painful Diabetic Peripheral Neuropathy: Systematic Review: Erratum

Free Access

In the June 2012 issue of The Clinical Journal of Pain in the article by Häuser et al, “Adverse Events Attributable to Nocebo in Randomized Controlled Drug Trials in Fibromyalgia Syndrome and Painful Diabetic Peripheral Neuropathy: Systematic Review,” some data were erroneous. In the following sentence of the ABSTRACT and DISCUSSION/Summary of main results, “Nocebo effects accounted for 72.0% of the drop outs in true drug groups in FMS” is incorrect. The correct data are as follows (see data in the results section): Nocebo effects accounted for 58.9% of the drop outs in true drug groups in FMS (DPN).

Back to Top | Article Outline

REFERENCE

Häuser W, Bartram C, Bartram-Wunn E, et al .

Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain. 2012;28(5):437–451


Copyright © 2013 by Lippincott Williams & Wilkins